Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Pharmacologic rationale for early G-CSF prophylaxis in cancer patients and role of pharmacogenetics in treatment optimization.

Critical reviews in oncology/hematology - 1 Oct 2009

Crea Francesco, Giovannetti Elisa, Zinzani Pier Luigi, Danesi Romano

Abstract excerpt

The use of recombinant human granulocyte colony stimulating factors (G-CSF) has become an integral part of supportive care during cytotoxic chemotherapy. Current guidelines recommend the use of G-CSF in patients with substantial risk of febrile neutropenia. However, little consensus exists about optimal timing and tailoring of this therapy. Based on the known effects of chemotherapy and G-CSF on bone marrow...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Agents
Share to Clinical Trials as Topic

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Genetic Predisposition to Disease

Share to Granulocyte Colony-Stimulating Factor

Share to Neoplasms

Share to Neutropenia

Share to Pharmacogenetics

Share to Practice Guidelines as Topic

Source

Identifiers

PMID: 19111474
DOI: 10.1016/j.critrevonc.2008.10.014

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Pharmacologic rationale for early G-CSF prophylaxis in cancer patients and role of pharmacogenetics in treatment optimization.PMID 19111474Read ↗

G-CSF and its receptor in myeloid malignancy.Semantic proximity Read ↗

Colony Stimulating Factor 3 Mutations and Myeloid Malignancies.Semantic proximity Read ↗

Advances in understanding postreceptor signaling in response to granulocyte colony-stimulating factor.Semantic proximity Read ↗

The role of the granulocyte colony-stimulating factor receptor (G-CSF-R) in disease.Semantic proximity Read ↗

Real-world incidence of febrile neutropenia despite primary prophylaxis with pegylated G-CSF: a prospective single centre cohort study from IndiaSemantic proximity Read ↗

Granulocyte colony-stimulating factor receptor: stimulating granulopoiesis and much more.Semantic proximity Read ↗

[G-CSF and Its Receptor in Hematonosis].Semantic proximity Read ↗

Cancer-induced systemic myeloid dysfunction: Implications for treatment and a novel nanoparticle approach for its correctionSemantic proximity Read ↗

Current approaches for risk stratification of infectious complications in pediatric oncology.Semantic proximity Read ↗

Chemotherapy characteristics are important predictors of primary prophylactic CSF administration in older patients with breast cancer.Semantic proximity Read ↗

Is granulocyte colony-stimulating factor therapy a risk factor for myelodysplasia/leukemia in patients with congenital neutropenia?Semantic proximity Read ↗

Impact of genetic polymorphisms determining leukocyte/neutrophil count on chemotherapy toxicity.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.